| Page 1913 | Kisaco Research
 

David H. Crean

Managing Director
Objective Capital Partners

David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities.

David H. Crean

Managing Director
Objective Capital Partners

David H. Crean

Managing Director
Objective Capital Partners

David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.

Prior to joining Objective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). Dr. Crean has led transaction execution in a wide range of specialty areas including aesthetic and therapeutic dermatology, OTC skin care, neurological disorders / CNS, pain, inflammation, ophthalmology, oncology and diagnostics/ detection. His corporate pharmaceutical experience spans research and development expertise in small molecules, biologics, prescription drugs, OTC products and medical devices.

Dr. Crean’s pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and/or growth of many commercial portfolios including: BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective Capital, Dr. Crean serves as a strategic business advisor for several life science companies, is an active member on BIOCOM’s Capital Development Committee and BIO International 2017 Partnering Committee and a contributing member on the Membership & Program Committees for the Association for Corporate Growth (ACG) in San Diego.

Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College.

Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.

 

Emma Taylor

CEO & Co-Founder
Naked Biome

Dr. Emma Taylor the CEO and co-founder of Naked Biome, a microbiome therapeutics company, focused in acne She is a UCLA-trained and board certified Dermatologist and Dermatopathologist, and former assistant professor of Dermatology and Dermatopathology at UCLA, where she c0-founded Naked Biome. She is also an inventor of 2 published patents, has published in notable journals such as Nature and the Journal of the American Academy of Dermatology, and is the author on more than 40 book chapters.

Emma Taylor

CEO & Co-Founder
Naked Biome

Emma Taylor

CEO & Co-Founder
Naked Biome

Dr. Emma Taylor the CEO and co-founder of Naked Biome, a microbiome therapeutics company, focused in acne She is a UCLA-trained and board certified Dermatologist and Dermatopathologist, and former assistant professor of Dermatology and Dermatopathology at UCLA, where she c0-founded Naked Biome. She is also an inventor of 2 published patents, has published in notable journals such as Nature and the Journal of the American Academy of Dermatology, and is the author on more than 40 book chapters.

 

Richard Andrews

CEO
Azitra

Mr.  Andrews has spent most of his career as a C level executive leading operations, finance, and commercial and clinical development for biotechnology firms focused on new products that address inflammatory disease. Mr. Andrews has been instrumental in translating research and academic discoveries into product development and advanced clinical programs, building alliances and partnerships and organizing operational teams. Financing processes led by Mr. Andrews have secured over $130M in equity funding for new ventures.

Richard Andrews

CEO
Azitra

Richard Andrews

CEO
Azitra

Mr.  Andrews has spent most of his career as a C level executive leading operations, finance, and commercial and clinical development for biotechnology firms focused on new products that address inflammatory disease. Mr. Andrews has been instrumental in translating research and academic discoveries into product development and advanced clinical programs, building alliances and partnerships and organizing operational teams. Financing processes led by Mr. Andrews have secured over $130M in equity funding for new ventures. His work has been primarily focused on skin disease, pneumonia, infant hypoxic ischemia and kidney failure. Early in his career, Mr. Andrews led the commercialization of several natural cell systems to prevent disease on fruits and vegetables and launched several DNA diagnostic tests for periodontal disease. Mr. Andrews received graduate degrees in physical biochemistry (MS), and technology management (SM) from Purdue University, and the Massachusetts Institute of Technology, respectively. He also has an undergraduate degree in Chemistry (BS) from Hobart College.

 

Jim Perkins

COO
Allies of Skin

Jim Perkins

COO
Allies of Skin

Jim Perkins

COO
Allies of Skin
 

Sergio Radovcic

Founder and CEO
STYR Labs

14x Entrepreneur, Former CEO @Inmoo, CTO @HealthiestYou, CEO @FitFul, 14x Ironman Finisher, 3x Badwater 135, Father of 3.

Sergio Radovcic

Founder and CEO
STYR Labs

Sergio Radovcic

Founder and CEO
STYR Labs

14x Entrepreneur, Former CEO @Inmoo, CTO @HealthiestYou, CEO @FitFul, 14x Ironman Finisher, 3x Badwater 135, Father of 3.

 
Animal Health Asia 2018 Chinese
24-25 Oct 2018
Hong Kong
亚洲动物健康创新论坛是一个B2B的高端论坛,它为正在 动物保健和营养领域 崛起的中国乃至亚太区企业提供了良好的展示平台。为正在融资或希望与全球跨国公司形成战略合作伙伴的新兴企业提供宝贵契机。我们的专场讨论旨在为各与会企业提供中国市场的准入指导,分享新兴企业如何运用创新技术防治动物疾病,以及分析科技发展趋向及其如何影响亚洲动保和营养市场。
Agriculture Events Calendar 2018